Joel Lewis serves as the Chief Executive Officer and President of Galectin Therapeutics, having guided the organization's corporate strategy and clinical operations. Bringing extensive financial management and executive restructuring experience to the role, he oversees the advancement of the company's core drug development pipelines, most notably its adaptive clinical trials evaluating proprietary galectin-3 inhibitors for advanced liver disease and MASH cirrhosis.